UEPM, a premier clinical trial search platform in Latin America and Massive Bio, a leader in AI-driven oncology solutions, have announced an expanded partnership.
The collaboration will extend Massive Bio’s reach across nine LATAM countries, including Mexico, Colombia, Brazil and Argentina, to improve clinical trial access and patient care.
Dr Selin Kurnaz PhD, Co-Founder and CEO, Massive Bio, said: “By leveraging UEPM’s extensive network and our AI technology, we can ensure that more patients in LATAM have access to cutting-edge therapies.”
Massive Bio’s advanced AI technology streamlines the clinical trial enrolment process, reducing the time and effort required for patient matching. This partnership will facilitate better access to clinical trials for cancer patients in LATAM, helping to bridge the gap between innovative treatments and the patients who need them most.
Dr Georgina Sposetti, CEO and Founder, UEPM, said: “This collaboration will significantly improve the accessibility and efficiency of finding suitable clinical trials for our cancer patients, ultimately enhancing their treatment outcomes and quality of life.”
The UEPM platform allows patients and healthcare providers to search for clinical trials that match specific medical conditions and treatment needs.
By integrating Massive Bio’s AI-driven solutions, UEPM can offer more accurate and timely clinical trial matches – increasing participation rates and advancing cancer research.
